Prevalence, Sociodemographic Differences, and Comorbidity in Pediatric Obesity

Maharaj Singh1, Sylvia Peña, Wendy Bauer

  • 1Maharaj Singh, PhD, Sylvia Peña, PhD, RN, Wendy Bauer, PhD, RN, Abir Bekhet, PhD, RN, HSMI, Maria Peña, PhD, RN, CNE, Kristin Haglund, PhD, RN, PNP, FNP, APRN, Shanna Doucette Knierim, MSN, APRN, CPNP-PC/AC, Marilyn Frenn, PhD, RN, CNE, ANEF, FTOS, FAAN, Marquette University College of Nursing, Milwaukee, WI.

Nursing Research
|August 18, 2026
PubMed

Insights

Pediatric obesity affects over 6% of hospitalized children, with higher rates in minority groups and lower income areas. Hospitalization offers a key chance to identify and treat this condition.

Area of Science:

  • Public Health
  • Pediatric Medicine
  • Health Disparities

Background:

  • Pediatric obesity is a significant public health issue impacting both immediate and long-term health.
  • Limited recent data exists on national estimates of obesity in hospitalized children.

Purpose of the Study:

  • To determine the prevalence of diagnosed obesity in hospitalized children.
  • To analyze sociodemographic variations and co-occurring conditions in obese pediatric inpatients.
  • Utilizing the 2021 National Inpatient Sample for comprehensive analysis.

Main Methods:

  • Cross-sectional analysis of pediatric hospitalizations (ages 2-17) from the 2021 National Inpatient Sample.
  • Obesity defined using ICD-10-CM codes.
  • Survey-weighted analyses and multivariable logistic regression to assess prevalence, comorbidities, and sociodemographic factors.

Main Results:

  • 6.29% of an estimated 961,529 pediatric hospitalizations had a documented obesity diagnosis.
  • Obesity prevalence was higher among Black, Hispanic, and Native American children, and inversely correlated with neighborhood income.
  • Obese children exhibited significantly higher rates of cardiometabolic, respiratory, and mental health comorbidities.

Conclusions:

  • Pediatric obesity in hospitalized children is linked to notable sociodemographic disparities and a substantial comorbidity burden.
  • Hospital admissions provide a critical window for identifying obese children and connecting them to necessary healthcare services.
Abstract

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Prevalence and Incidence01:08

Prevalence and Incidence

In statistical epidemiology and health sciences, two essential metrics—prevalence and incidence—are fundamental for understanding disease dynamics within a population. These measures enable public health officials, epidemiologists, and researchers to assess the burden of diseases, allocate resources effectively, and design impactful public health policies and interventions.
Prevalence indicates the proportion of individuals in a population who have a specific disease or health condition at a...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...